FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549
------------------------

STATEMENT C	F CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average	burden										
hours per response	: 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Mika Yuval				2. Issuer Name and Ticker or Trading Symbol Orchestra BioMed Holdings, Inc. [ OBIO ]									eck all app Direc	tor	10	% Ow	/ner		
(Last)	st) (First) (Middle) O ORCHESTRA BIOMED HOLDINGS, INC.			3. Date of Earliest Transaction (Month/Day/Year) 05/08/2024								X Officer (give title Other (specify below)  See Remarks							
150 UNION SQUARE DRIVE				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) NEW HO	OPE PA	. 1	8938													filed by One filed by Mon			
(City)	(St	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instr													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)			Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired Disposed Of (D) (Instr. 5)					Benefi	ties cially Following	Form: Direct (D) or Indirect (I) (Instr. 4)	ect E	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
									Code	v	Amount (A) (D)		() or ()	Price	Transa	Transaction(s) (Instr. 3 and 4)			1115(1.4)
Common Stock, par value \$0.0001 per share ("Common Stock") 05/08/				05/08/	2024		A		69,333(1	(1) A		<b>\$</b> 0	158,905		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date (Month/Day/Year)  3A. Deemed Execution Date, if any (Month/Day/Year)				Transaction of Code (Instr. Derivate		vative irities ired r osed )	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	(D) rect	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amo or Num of Shar	nber					

## **Explanation of Responses:**

1. Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 10,400 RSUs will vest on May 18, 2025, and (ii) the remaining 58,933 RSUs will vest in equal installments on August 18, 2025, November 18, 2025, December 18, 2025, May 18, 2026, August 18, 2026, November 18, 2026, March 25, 2027, May 18, 2027, November 18, 2027, November 18, 2027, November 18, 2027, November 18, 2027, May 18, 2027, November 18, 2027, May 18, 2027, November 18, 2028, subject to the Reporting Person's continuous service through such dates.

## Remarks:

General Manager and Chief Technology Officer, Bioelectronic Therapies

/s/ Matthew R. Schob, 05/10/2024 Attorney-in-Fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.